申请人:Schering Aktiengesellschaft
公开号:US04766128A1
公开(公告)日:1988-08-23
Substituted ergolines of the formula ##STR1## and their acid addition salts, wherein the urea side chain in the 8-position can be in the d.alpha.- or .beta.-configuration, C.sub.2 C.sub.3 and C.sub.9 C.sub.10 are a CC single or C.dbd.C double bond, and R is hydrogen or NR'R" wherein R'R" is O.sub.2, H.sub.2, C.sub.1-4 -dialkyl, or, together, they form a 3- to 9-membered ring, or R' and R" individually are hydrogen, C.sub.1-4 -alkyl, or C.sub.1-10- -acyl, R.sup.1 is hydrogen, C.sub.1-4 -alkyl, C.sub.1-10 -acyl, C.sub.6-8 -aryl, or C.sub.1-4 -alkylsulfonyl, R.sup.2 is hydrogen or halogen if C.sub.2 C.sub.3 is a C.dbd.C double bond, or hydrogen if C.sub.2 C.sub.3 is a CC single bond, R.sup.6 is C.sub.1-4 -alkyl, show a pronounced effect on the central nervous system and are suitable, for example, as antidepressants, neuroleptics, or antihypertensives.
式为 ##STR1## 的替代麦角酸衍生物及其酸加成盐,其中8位的尿素侧链可以是d.alpha.-或.beta.-构型,C.sub.2 C.sub.3和C.sub.9 C.sub.10是CC单键或C.dbd.C双键,R是氢或NR'R",其中R'R"是O.sub.2、H.sub.2、C.sub.1-4-双烷基或共同形成3-9成员环,或者R'和R"分别是氢、C.sub.1-4-烷基或C.sub.1-10-酰基,R.sup.1是氢、C.sub.1-4-烷基、C.sub.1-10-酰基、C.sub.6-8-芳基或C.sub.1-4-烷基磺酰基,R.sup.2是氢或卤素,如果C.sub.2 C.sub.3是C.dbd.C双键,或者氢,如果C.sub.2 C.sub.3是CC单键,R.sup.6是C.sub.1-4-烷基,对中枢神经系统有显著影响,例如作为抗抑郁剂、神经类药物或降压药物。